ストックスクリーナーアプリを入手
0.9102
1.21%
0.0109
前日終値:
$0.8993
開ける：
$0.9062
24時間の取引高:
147.71K
Relative Volume:
1.28
時価総額：
$51.95M
収益：
$33.79M
当期純損益:
$-18.67M
株価収益率:
-1.517
EPS:
-0.6
ネットキャッシュフロー:
$-19.17M
1週間 パフォーマンス:
-0.62%
1か月 パフォーマンス:
-12.48%
6か月 パフォーマンス:
+1.13%
1年 パフォーマンス:
-26.00%
1日の値動き範囲:
$0.9062
$0.9501
1週間の範囲:
$0.89
$0.97
52週間の値動き範囲:
$0.70
$2.15
Cytosorbents Corp Stock (CTSO) Company Profile
CTSO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.9102 | 51.95M | 33.79M | -18.67M | -19.17M | -0.60 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-07 | 開始されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2020-09-17 | 開始されました | Jefferies | Buy |
| 2020-09-01 | 開始されました | SVB Leerink | Outperform |
| 2017-08-08 | 繰り返されました | Maxim Group | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-05-24 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 繰り返されました | MLV & Co | Buy |
| 2015-04-01 | 繰り返されました | MLV & Co | Buy |
| 2015-03-05 | 開始されました | MLV & Co | Buy |
| 2015-02-25 | 開始されました | WBB Securities | Speculative Buy |
| 2015-01-27 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Cytosorbents Corp (CTSO) 最新ニュース
CytoSorbents to Present at Piper Sandler's 36th Annual Healthcare Conference | CTSO Stock News - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
Granahan Investment Management Reduces Stake in CytoSorbents Cor - GuruFocus.com
FY2024 EPS Estimates for Cytosorbents Decreased by Analyst - Defense World
FY2024 EPS Estimate for Cytosorbents Decreased by Analyst - MarketBeat
Cytosorbents Corporation (NASDAQ:CTSO) Q3 2024 Earnings Call Transcript - Insider Monkey
CytoSorbents And Converge Biotech Announce Strategic - GlobeNewswire
CytoSorbents Expands Into India Through Strategic Converge Biotech Partnership | CTSO Stock News - StockTitan
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - MarketBeat
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ... - Yahoo Finance
Cytosorbents Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CytoSorbents Corporation’s Q3 2024 Financial Highlights - TipRanks
CytoSorbents: Q3 Earnings Snapshot - CT Insider
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results - StockTitan
CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ah - GuruFocus.com
CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
CytoSorbents (STU:HQE1) 3-Year EPS without NRI Growth Rate : -38.10% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 3-Year EBITDA Growth Rate : -37.70% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 3-Year FCF Growth Rate : -39.10% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 5-Day RSI : 14.64 (As of Nov. 05, 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) Operating Income : €-23.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification - StockTitan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Cytosorbents (CTSO) to Release Earnings on Thursday - MarketBeat
Cytosorbents (NASDAQ:CTSO) and Caliber Imaging & Diagnostics (OTCMKTS:LCDX) Critical Comparison - Defense World
Analyst Scoreboard: 5 Ratings For CytoSorbents - Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts - Benzinga
FDA begins review of CytoSorbents' bleeding reduction device - Investing.com
FDA begins review of CytoSorbents' bleeding reduction device By Investing.com - Investing.com UK
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review - StockTitan
CytoSorbents (STU:HQE1) Forward Dividend Yield % : 0.00% (As of Nov. 05, 2024) - GuruFocus.com
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - MarketBeat
Cytosorbents Co. (NASDAQ:CTSO) Short Interest Down 5.7% in September - MarketBeat
CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
CytoSorbents maintains Buy rating from B.Riley with no change in target price - Investing.com
Cytosorbents announces $20 million "at the market" equity offering - Investing.com
Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits - Quantisnow
DrugSorb-ATR seeks FDA priority review for surgery bleeding - Investing.com
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update - The Manila Times
Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 81% loss from investing in the stock three years ago - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Cytosorbents Corp (CTSO) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
大文字化:
|
ボリューム (24 時間):